Agios Pharmaceuticals, Inc.
AGIO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $36,498 | $26,823 | $14,240 | $0 |
| % Growth | 36.1% | 88.4% | – | – |
| Cost of Goods Sold | $4,165 | $9,504 | $1,704 | $18,777 |
| Gross Profit | $32,333 | $17,319 | $12,536 | -$18,777 |
| % Margin | 88.6% | 64.6% | 88% | – |
| R&D Expenses | $301,286 | $288,903 | $279,910 | $256,973 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $156,784 | $119,903 | $121,673 | $121,445 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$18,777 |
| Operating Expenses | $458,070 | $408,806 | $401,583 | $359,641 |
| Operating Income | -$425,737 | -$391,487 | -$389,047 | -$378,418 |
| % Margin | -1,166.5% | -1,459.5% | -2,732.1% | – |
| Other Income/Exp. Net | $1,143,706 | $39,399 | $157,246 | $21,908 |
| Pre-Tax Income | $717,969 | -$352,088 | -$231,801 | -$356,510 |
| Tax Expense | $44,244 | $0 | $0 | $0 |
| Net Income | $673,725 | -$352,088 | -$231,801 | $1,604,715 |
| % Margin | 1,845.9% | -1,312.6% | -1,627.8% | – |
| EPS | 11.86 | -6.33 | -4.23 | -6.36 |
| % Growth | 287.4% | -49.6% | 33.5% | – |
| EPS Diluted | 11.64 | -6.33 | -4.23 | -6.36 |
| Weighted Avg Shares Out | 56,807 | 55,651 | 54,789 | 60,447 |
| Weighted Avg Shares Out Dil | 57,889 | 55,651 | 54,789 | 60,447 |
| Supplemental Information | – | – | – | – |
| Interest Income | $48,083 | $33,344 | $12,793 | $836 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5,653 | $6,623 | $8,564 | $18,777 |
| EBITDA | -$420,084 | -$384,864 | -$380,483 | -$337,733 |
| % Margin | -1,151% | -1,434.8% | -2,671.9% | – |